1. Kahn SE，Hull RL，Utzschneider KM.Mechanism linking obesity to insulin resistance and type 2 diabetes. Nature，2006，444：840-846.

2. Shoelson SE，Lee J，Goldfine AB.Inflammation and insulin resistance.J Clin Invest，2006，116：1793-1801.

3. Scherer PE.Adipose tissue：from lipid storage compartment to endocrine organ.Diabetes，2006，55：1537-1545.

4. Yang Q，Graham TE，Mody N，et al.Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes.Nature，2005，436：356-362.

5. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes.Diabetologia，2003，46：3-19.

6. Rosen ED，Spiegelman BM.Adipocytes as regulators of energy balance and glucose homeostasis.Nature.2006，444：847-853.

7.李秀钧.代谢综合征.北京：人民卫生出版社，2007.

8. Gress TW，Nieto FJ，Shahar E，et al.Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus.N Engl J Med，2000，342（13）：905-912.

9. Fukuhara A，Matsuda M，Masako Nishizawa，et al.Visfatin：a protein secreted by visceral fat that mimics the effects of insulin.Science，2005，307：426-430.

10. Haider DG，Schaller G，Kapiotis S，et al.The release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia，2006，49：1909-1914.

11. Ochard TJ，Temprosa M，Goldberg BR，et al.The effect of metformin and intensive lifestyle intervention on the metabolic syndrome：The Diabetes Prevention Program randomized trial.Ann intern Med.2005，142：611-619.

12.史轶蘩.肥胖症临床诊治手册.上海：上海科学技术出版社，2001.

13.裴海成，刘志民，邱明才，等.实用肥胖病治疗学.北京：人民军医出版社，2006.

14. Orchard TJ，Temprosa M，Goldberg R，et al.Diabetes Prevention Program Research Group.The effect of metformin and intensive lifestyle intervention on the metabolic syndrome：the Diabetes Prevention Program randomizedtrial. Ann Intern Med，2005，142：611-619.

15. Zillich AJ，Garg J，Basu S，et al.Thiazide diuretics potassium the development of diabetes：a quantitative review.Hypertension，2006，48：219-224.

16. Schupp M，Janke J，Clasen R，et al.Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptorgamma activity.Circulation，2004，109：2054-2057.

17. DREAM（Diabetes REduction Assessment with ramipril rosiglitazone Medication）Trial Investigators；Gerstein HC，Yusuf S，Bosch J，et al.Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose：a randomised controlled trial.Lancet，2006，368：1096-1105.

18. Maggio CA，Pi-Sunyer FX.Obesity and type 2 diabetes. Endocrinol Metab Clin N Am，2003，32：805-822.

19. Pischon T，Sharma AM.Use of beta-blockers in obesity hypertension：potential role of weight gain.Obes Rev，2001，2：275-280.

20.中华医学会糖尿病学分会.中国2型糖尿病防治指南. 2010年版.北京：北京大学医学出版社，2011.